Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FODZYME is a proprietary oral enzyme supplement developed by Kiwi Biosciences to address digestive discomfort associated with the ingestion of FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols). The product contains a blend of three primary enzymes: fructan hydrolase, which breaks down fructans; lactase, which targets lactose; and alpha-galactosidase, which degrades galacto-oligosaccharides (GOS). By enzymatically converting these hard-to-digest carbohydrates into smaller, more absorbable molecules during meal consumption, FODZYME aims to prevent the colonic fermentation that typically triggers symptoms like bloating, gas, and abdominal pain in individuals with Irritable Bowel Syndrome (IBS) or general FODMAP sensitivities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FODZYME.